Table 1 Clinical and treatment characteristics for all patients
|  | Center 1 (n = 453) | Center 2 (n = 110) |
|---|---|---|
Age (years, mean ± SD) * | 55.34 ± 11.12 | 59.2 ± 10.6 |
Sex (%) | ||
Male | 299 (66.0%) | 85 (77.3%) |
Female | 154 (34.0%) | 25 (22.7%) |
Clinical stage (%) | ||
II | 93 (20.5%) | 11 (10.0%) |
III | 321 (70.9%) | 97 (88.2%) |
IV | 39 (8.6%) | 2 (1.8%) |
Pretreatment T stage (%) | ||
2 | 10 (2.2%) | 1 (0.9%) |
3 | 269 (59.4%) | 51 (46.4%) |
4 | 174 (38.4%) | 58 (52.7%) |
Lymph node status (%) | ||
LN negative | 94 (20.8%) | 14 (12.7%) |
LN positive | 359 (79.2%) | 96 (87.3%) |
Location (%) | ||
 > 10 cm | 68 (15.0%) | 10 (9.1%) |
5–10 cm | 235 (51.9%) | 41 (37.3%) |
 < 5 cm | 150 (33.1%) | 59 (53.6%) |
Pretreatment CEA (%) | ||
 < 5 (normal) | 245 (54.1) | 52 (47.3%) |
 ≥ 5 (abnormal) | 208 (45.9%) | 58 (52.7%) |
Pretreatment CA199 (%) | ||
 < 39 (normal) | 392 (86.5%0 | 93 (84.5%) |
 ≥ 39 (abnormal) | 61 (13.5%) | 17 (15.5%) |
Neoadjuvant therapy (%) | ||
Neoadjuvant chemoradiotherapy | 403 (89.0%) | 110 (100.0%) |
Neoadjuvant chemotherapy | 50 (11.0%) | – |
Mandard grade (%) | ||
1 | 104 (23.0%) | 25 (22.7%) |
2 | 125 (27.6%) | 31 (28.2%) |
3 | 138 (30.5%) | 29 (26.4%) |
4 | 80 (17.7%) | 25 (22.7%) |
5 | 6 (1.3%) | – |